

RISK ASSESSMENT OF HCV SEROCOVERSION IN HEMODIALYSIS PATIENTS

Thesis

*Submitted for Partial Fulfillment of
M. Sc. Degree in Internal Medicine*

By

Abdel-Aziz Mahmoud Mohammed

M.B.B.Ch

Supervised by

Prof. Dr. /Maha Abdel-Aziz Eltouny

Professor of Internal Medicine

Faculty of Medicine

Ain Shams University

Asst. Prof. Dr./Marcel William Keddeas

Assistant Professor of Internal Medicine

Faculty of Medicine

Ain Shams University

Dr. /Ossama Ashraf Ahmed

Lecturer of Internal Medicine

Faculty of Medicine

Ain Shams University

Faculty of Medicine

Ain Shams University

2011

تقييم مخاطر العدوى بالفيروس الكبدي الوبائي سي في مرضي الغسيل الكلوي

رسالة

توطئة للحصول على درجة الماجستير
في أمراض الباطنة العامة

مقدمة من

الطبيب / عبدالعزيز محمود محمد محمد
بكالوريوس الطب والجراحة

تحت إشراف

أ. د. / مها عبدالعزيز التوني

أستاذ الباطنة العامة
كلية الطب - جامعة عين شمس

أ.م.د. / مارسيل وليم قديس

أستاذ مساعد الباطنة العامة
كلية الطب - جامعة عين شمس

د. / اسامة اشرف احمد

مدرس الباطنة العامة
كلية الطب - جامعة عين شمس

كلية الطب
جامعة عين شمس

٢٠١١

Summary

Hepatitis C virus infection has recently become the major cause of chronic liver disease among patients on chronic HD who are at high risk of infection by HCV. Risk factors as dialytic age, blood transfusion and possibility of nosocomial HCV transmission have been suggested.

Preventing HCV infection, the most important public health issue in HD units in Egypt. This means stopping or reducing the transmission of HCV from an infected person to a person who is not infected.

The aim of this study was to determine the risk factors of HCV seroconversion in two HD units in upper Egypt, and to determine the effect of isolation policy on the incidence of HCV seroconversion in both units as well as evaluation of infection control measures.

Our study included 80 chronic HD patients divided to two groups: Group of no isolation of HCV seropositive patients (group A), this group included 45 patients, and group of isolation (group B), included 35 patients. All included patients had complete files and remain on HD for more than 2 consecutive serology tests. The patients enrolled in the study

List of Contents

| Title | Page No. |
|---|----------|
| Introduction & aim of the work | 1 |
| Review of the literature: | |
| ▪ Chapter (1): Hepatitis C Virus (HCV) | 5 |
| ▪ Chapter (2): HCV infection in haemodialysis (HD)..... | 47 |
| ▪ Chapter (3): Infection control policy and Isolation precautions in HD | 63 |
| Patients and methods | 97 |
| Results | 104 |
| Discussion | 135 |
| Summary | 150 |
| Conclusion | 154 |
| Recommendations | 155 |
| References | 156 |
| Arabic summary | — |

List of Figures

| Fig. No. | Title | Page No. |
|---------------------|---|----------|
| Figure (1): | Hepatitis C virus in Egypt compared to other countries in the world | 10 |
| Figure (2): | Natural history of HCV infection..... | 14 |
| Figure (3): | Schematic design of HCV | 15 |
| Figure (4): | Electron microscopy of HCV | 16 |
| Figure (5): | HCV components | 16 |
| Figure (6): | HCV genotypes | 19 |
| Figure (7): | Genome of HCV | 19 |
| Figure (8): | Hepatitis C infection in the US by source | 23 |
| Figure (9): | Lifecycle of HCV | 29 |
| Figure (10): | Components of the antiviral immune response in HCV infection | 29 |
| Figure (11): | Serologic results in cases of acute hepatitis C that do not progress to chronic infection (A) and in cases of chronic hepatitis C | 39 |

| | |
|---|-----|
| Figure (12): Testing algorithm for HCV infection in asymptomatic patients | 41 |
| Figure (13): Conceptual model of factors influencing adherence to hand hygiene practices | 70 |
| Figure (14): Comparison between both groups as regard dialytic age | 109 |
| Figure (15): Comparison between both groups as regard laboratory data | 111 |
| Figure (16): Comparison between negative and positive serology as regard laboratory data among group A | 114 |
| Figure (17): Comparison between negative and positive serology as regard general data among group B | 116 |
| Figure (18): Comparison between both groups as regard seroconversion rate of HCV Ab | 122 |
| Figure (19a): Comparison between both groups as regard supplies in both units | 125 |
| Figure (19b): Comparison between both groups as regard mean score of supplies..... | 126 |

| | |
|--|-----|
| Figure (20 a): Comparison between both groups as regard processes related to the patients..... | 129 |
| Figure (20 b): Comparison between both groups as regard processes related to the patients | 130 |
| Figure (20c): Comparison between both groups as regard processes related to the patients | 131 |
| Figure (20d): Comparison between both groups as regard mean score of processes related to the patients | 132 |
| Figure (21a): Comparison between both groups as regard processes not related to the patients | 134 |
| Figure (21b): Comparison between both groups as regard mean score of processes not related to the patients..... | 135 |

List of Tables

| Table No. | Title | Page No. |
|-------------------|--|----------|
| Table (1): | Contraindications to Treatment of HCV Infection with Interferon Plus Ribavirin | 44 |
| Table (2): | Prevalence of HCV infection in hemodialysis patients from various countries | 50 |
| Table (3): | Annual reports of Egyptian registry from 1996 -2008 | 51 |
| Table (4): | Aseptic technique | 73 |
| Table (5): | Hygienic precautions for hemodialysis (general) | 86,87 |
| Table (6): | Hygienic precautions for hemodialysis (dialysis machines) | 87,88 |
| Table (7): | Activities performed by the staff of HD unit and definition of when universal precautions must be..... | 102 |
| Table (8): | Comparison between both groups as regard general and laboratory data..... | 108 |

| | |
|--|-----|
| Table (9): Comparison between negative and positive serology as regard lab. data among both groups..... | 110 |
| Table (10): Comparison between both groups as regard general data among group A | 112 |
| Table (11): Comparison between negative and positive serology as regard lab. data among group A | 113 |
| Table (12): Comparison between negative and positive serology as regard general data among group B | 115 |
| Table (13): Comparison between negative and positive serology as regard laboratory data among group B | 117 |
| Table (14): The relation between HCV seropositivity in both groups as regard Dialytic age, history of blood transfusion, no. of blood transfusion and other HCV related risk factors..... | 118 |
| Table (15): Comparison between all Seronegative and seropositive patients in both groups as regard dialytic age, gender and other risk factors.. | 119 |

| | |
|--|---------|
| Table (16): Comparison between group A and group B as regard annual rates of seroconversion from 2008 to 2010 | 120 |
| Table (17): Comparison between both groups as regard seroconversion rate..... | 121 |
| Table (18): General evaluation of HD units | 123 |
| Table (19): Comparison between both groups as regard supplies in both units | 124 |
| Table (20): Comparison between both groups as regard processes related to the patients in both units | 127,128 |
| Table (21): Comparison between both groups as regard processes not related to the patients in both units | 133 |

List of Abbreviations

| | |
|---------------|---|
| ALT | Alanine transaminases |
| CDC | Center of disease control |
| CTC | Cytotoxic T cells |
| CVC | Central venous catheter |
| CXCL10 | ...C-X-C motif chemokine 10 |
| EDHS | Egyptian demographic health survey |
| EIA | Enzyme immunoassay |
| ERBP | European renal best practice. |
| ESRD | End stage renal disease |
| FDA | Food and drug administration |
| HBV | Hepatitis B virus |
| HCV | Hepatitis C virus |
| HD | Haemodialysis |
| HIV | Human immune virus |
| IC | Infection control |
| IL | Interleukin |
| INF | Interferon |
| IP-10 | Interferon gamma-induced protein-10 |

KIDGO .. Kidney international disease improving global outcome.

KDOQI... kidney disease outcome quality initiatives.

MENA ... The middle east and north Africa

MHC Major histocompatibility complex

NAT Nucleic acid test

NIH National institute of health

NS Non structural

PCR Polymerase chain reaction

PPE Personal protective equipments

RO Reverse osmosis

STD Sexual transmitted diseases

SVR Sustained virological response

TH T helper

TMA Transcription-mediated amplification.

TNF Tissue necrosis factor

USPSTF.. US preventive services task force.

UVGI Ultraviolet germicidal irradiation.

WHO World health organization

Introduction

End stage renal disease (ESRD) Patients have been increased in the last decade, leading to rapid increase in haemodialysis units. Within these units patients may suffer many risks; one of the most important risks is infection. Viruses are considered from the most important causative agents of infection in haemodialysis units, one of these viruses is hepatitis C virus (HCV) which is a major complication among haemodialysis patients allover the world (**Furusyo et al., 2000**).

Hepatitis C virus infection is the most common cause of chronic hepatitis in haemodialysis patients therefore liver disease is a significant cause of morbidity and mortality among ESRD patients (**Fabrizi et al., 2002**).

Prevalence of Anti-HCV antibody among haemodialysis patients is constantly higher than in healthy populations, suggesting that dialysis patients may be at higher risk for acquiring HCV. The major risk factor for HCV infection in haemodialysis patients are blood transfusion, the number of blood transfusions and duration of dialysis (**Dussol et al., 1996**).

Prevention of HCV infection, the most important public health issue in Egypt is to prevent people from getting infected

Introduction and Aim of the Work

with HCV. This means stopping or reducing the transmission of HCV from an infected person to a person who is not infected. It is also very important to learn how to avoid iatrogenic infection (**Karmochkine et al., 2006**).

Iatrogenic transmission of HCV is possible when disinfection and sterilization techniques are inadequate and contaminated equipment is shared among patients. In particular, studies have shown that HCV infection can occur among patients on haemodialysis, due to poor infection control, and the sharing of contaminated medical vials and supplies (**Frank et al., 2000**).

Routes other than blood transfusion play a role in the spread of HCV in haemodialysis patients, Molecular studies of HCV implicate nosocomial transmission of the virus in haemodialysis units (**Alfurayh et al., 2000**).

Lack of strict adherence to standard precautions by staff and sharing of articles (such as multidose vials, tourniquets, etc) may be the main mode of nosocomial HCV spread among haemodialysis patients (**Jadoul et al., 2000**).

The isolation of HCV-infected patients is not recommended as an alternative to strict infection-control procedures for preventing transmission of blood-borne pathogens. If nosocomial transmission continues to occur, despite reinforcement and audit of the precautions, a local

Introduction and Aim of the Work

isolation policy may be deemed necessary. HCV infected patients should be treated by dedicated staff in a separate room, area, or shift, as there is no rationale for using dedicated machines. It should be realized that accepting the ‘need’ for isolation equates to accepting the impossibility of full implementation of basic hygienic precautions, a regrettable situation that entails the risk of transmission of pathogens other than HCV (**Allander et al., 2008**).

Some prospective observational studies have reported a reduction of HCV transmission after the reinforcement of basic hygienic precautions without any isolation measures. In particular one Belgian prospective multicenter study showed a reduction from 1.4% to 0% of a year incidence of seroconversion for HCV. This demonstrated that complete prevention of HCV transmission to HD patients was possible in the absence of any isolation policy (**Jadoul et al., 2000**).

Additional arguments against relay on the use of isolation to prevent transmission of HCV include the possibility of increased the risk of HCV infection with more than one genotype and the time of HCV infection and seroconversion (**Scoroeter et al., 2005**).

On the other hand the seroconversion time “window” can be over a year, and has a median length of 5 months in HD patients even with third generation EIA tests. This will result in